XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:
 
Three Months Ended September 30,Nine Months Ended September 30,
(in thousands)2021202020212020
Included in research and development expense$174 $104 $286 $251 
Included in selling, general and administrative expense766 258 1,958 570 
Total stock-based compensation expense$940 $362 $2,244 $821 
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards
The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
 
Nine Months Ended September 30,
20212020
Risk-free interest rate0.95 %0.44 %
Dividend yield%%
Expected volatility of Cardiff Oncology common stock108 %105 %
Expected term6.0 years5.9 years
Summary of Stock Option Activity and of Changes in Stock Options Outstanding
A summary of stock option activity and changes in stock options outstanding is presented below:
 
Total OptionsWeighted-Average
Exercise Price
Per Share
Intrinsic
Value
Balance outstanding, December 31, 20201,860,507 $7.43 $27,963,363 
Granted1,721,314 $7.48  
Canceled / Forfeited(10,770)$2.55  
Expired(4,219)$216.00  
Balance outstanding, September 30, 20213,566,832 $7.22 $7,522,769 
Exercisable at September 30, 20211,281,604 $8.96 $5,103,890 
Vested and expected to vest at September 30, 20213,466,323 $7.28 $7,344,075 
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
A summary of the RSU activity is presented below:
Total Restricted Stock UnitsWeighted-Average
Grant Date Fair Value
Per Share
Intrinsic Value
Non-vested RSUs outstanding, December 31, 2020491 $147.60 $8,833 
Vested(491)$147.60 
Non-vested RSUs outstanding, September 30, 2021— $— $— 
Summary of Warrant Activity and Changes in Warrants Outstanding
A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
 
Total WarrantsWeighted-Average
Exercise Price
Per Share
Weighted-Average
Remaining Contractual
Term
Balance outstanding, December 31, 20205,260,992 $5.19 4.1 years
Exercised(770,833)$1.64 
Balance outstanding, September 30, 20214,490,159 $5.80 3.2 years
Schedule of Preferred Stock
A summary of our Company's classes of preferred stock is presented below:
Shares outstanding
ClassPar valueShares designatedLiquidation preferenceAs of September 30,
2021
As of December 31,
2020
Series A Convertible Preferred Stock$0.001 277,100 $606,000 60,600 60,600 
Series B Convertible Preferred Stock$0.001 8,860 None— — 
Series C Convertible Preferred Stock$0.001 200,000 None— — 
Series D Convertible Preferred Stock$0.0001 154,670 None— — 
Series E Convertible Preferred Stock$0.001 865,824 None655,044 655,044